FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns an antisense compound for reducing expression of superoxide dismutase 1 (SOD-1), where antisense compound has the following formula: mCes Aeo Ges Geo Aes Tds Ads mCds Ads Tds Tds Tds mCds Tds Ads mCeo Aes Geo mCes Te (sequence of nitrogen bases SEQ ID NO: 725) or a pharmaceutically acceptable salt thereof. Group of inventions also relates to a pharmaceutical composition for reducing the expression of superoxide dismutase 1 (SOD-1) containing said antisense compound or a pharmaceutically acceptable salt thereof; method of treating or preventing SOD-1 related neurodegenerative disorder or SOD-1 related ALS, involving administering said antisense compound or its pharmaceutically acceptable salt.
EFFECT: group of inventions provides treating or preventing the SOD-1 related neurodegenerative disorder or SOD-1 related ALS.
17 cl, 19 ex, 71 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS | 2014 |
|
RU2686080C2 |
| COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | 2014 |
|
RU2670614C9 |
| COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | 2015 |
|
RU2703411C2 |
| COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | 2016 |
|
RU2736574C2 |
| COMPOSITIONS AND METHODS OF MODULATING APOLIPOPROTEIN C-III EXPRESSION | 2014 |
|
RU2650510C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
| COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR EXPRESSION B | 2015 |
|
RU2701645C2 |
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
